{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T04:52:32Z","timestamp":1794027152446,"version":"4.8.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.diagmicrobio.2025.117138","type":"journal-article","created":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T01:23:32Z","timestamp":1759627412000},"page":"117138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["In vitro activity of essential antimicrobial agents, including ceftazidime\/avibactam, imipenem\/relebactam, and cefiderocol, against carbapenem-resistant Gram-negative bacteria primarily harboring the IMP-type carbapenemase gene in the Kinki region of Japan"],"prefix":"10.1016","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9290-6031","authenticated-orcid":false,"given":"Tomokazu","family":"Kuchibiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Niki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsutoshi","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Sawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2025.117138_bib0001","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"10.1016\/j.diagmicrobio.2025.117138_bib0002","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/cid\/cix893","article-title":"Carbapenemase-producing organisms: a global scourge","volume":"66","author":"Bonomo","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.diagmicrobio.2025.117138_bib0003","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/j.jiac.2021.07.021","article-title":"Comparison of the performance of three carbapenem inactivation methods for the detection of carbapenemase-producing gram-negative bacilli","volume":"27","author":"Kuchibiro","year":"2021","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.diagmicrobio.2025.117138_bib0004","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1128\/CMR.00001-07","article-title":"Carbapenemases: the versatile \u03b2-lactamases","volume":"20","author":"Queenan","year":"2007","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.diagmicrobio.2025.117138_bib0005","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1093\/jac\/dkr256","article-title":"Molecular characterization of blaNDM-1 in an Acinetobacter baumannii strain isolated in Germany in 2007","volume":"66","author":"Pfeifer","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2025.117138_bib0006","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/jac\/dkp498","article-title":"Development of a set of multi-plex PCR assays for the detection of genes encoding important beta-lactamases in Enterobacteriaceae","volume":"65","author":"Dallenne","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2025.117138_bib0007","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1128\/JCM.00234-13","article-title":"Detection of IMP metallo-\u03b2-lactamase in carbapenem-nonsusceptible Enterobacteriaceae and non-glucose-fermenting gram-negative rods by immunochromatography assay","volume":"51","author":"Notake","year":"2013","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2025.117138_bib0008","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1128\/JCM.05247-11","article-title":"Value of the modified Hodge test for detection of emerging carbapenemases in Enterobacteriaceae","volume":"50","author":"Girlich","year":"2012","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2025.117138_bib0009","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/clinids\/10.4.867","article-title":"Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns","volume":"10","author":"Jarlier","year":"1988","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2025.117138_bib0010","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1128\/JCM.38.5.1791-1796.2000","article-title":"Occurrence and detection of AmpC beta-lactamases among Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates at a veterans medical center","volume":"38","author":"Coudron","year":"2000","journal-title":"J. Clin. Microbiol"},{"key":"10.1016\/j.diagmicrobio.2025.117138_bib0011","article-title":"Performance standards for antimicrobial susceptibility testing","volume":"33th ed","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2023"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2025.117138_bib0012","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2025.117138_bib0013","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jgar.2024.05.009","article-title":"In vitro activity of cefiderocol against carbapenemase-producing and meropenem-non-susceptible gram-negative bacteria collected in the Japan Antimicrobial Resistant Bacterial Surveillance","volume":"38","author":"Kayama","year":"2024","journal-title":"J Glob Antimicrob Resist"},{"issue":"Suppl 7","key":"10.1016\/j.diagmicrobio.2025.117138_bib0014","doi-asserted-by":"crossref","first-page":"S565","DOI":"10.1093\/cid\/ciz830","article-title":"Treatment options for carbapenem-resistant gram-negative bacterial infections","volume":"69","author":"Doi","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2025.117138_bib0015","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02729-16","article-title":"Global molecular epidemiology of IMP-producing Enterobacteriaceae","volume":"61","author":"Matsumura","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2025.117138_bib0016","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1093\/jac\/dkw239","article-title":"Spotlight on ceftazidime\/avibactam: a new option for MDR gram-negative infections","volume":"71","author":"Falcone","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2025.117138_bib0017","first-page":"2286","article-title":"Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa","volume":"68","author":"Livermore","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2025.117138_bib0018","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02209-16","article-title":"In vitro activity of imipenem-relebactam against gram-negative ESKAPE pathogens isolated by clinical laboratories in the United States in 2015 (Results from the SMART Global Surveillance Program)","volume":"61","author":"Lob","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2025.117138_bib0019","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1128\/AAC.04759-14","article-title":"Complete nucleotide sequence of the IncN plasmid encoding IMP-6 and CTX-M-2 from emerging carbapenem-resistant Enterobacteriaceae in Japan","volume":"59","author":"Kayama","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2025.117138_bib0020","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02235-21","article-title":"Vitro antibacterial activity of imipenem\/relebactam against clinical isolates in Japan","volume":"10","author":"Kurihara","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.diagmicrobio.2025.117138_bib0021","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1128\/AAC.00860-06","article-title":"FR264205, against Pseudomonas aeruginosa","volume":"51","author":"Takeda","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2025.117138_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106633","article-title":"Clinical data from studies involving novel antibiotics to treat multidrug-resistant gram-negative bacterial infections","volume":"60","author":"Kanj","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2025.117138_bib0024","year":"2024","journal-title":"FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria"},{"issue":"8","key":"10.1016\/j.diagmicrobio.2025.117138_bib0025","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00345-17","article-title":"Population pharmacokinetics of tigecycline in critically ill patients with severe infections","volume":"61","author":"Xie","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2025.117138_bib0026","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01454-17","article-title":"In Vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against gram-negative bacteria","volume":"62","author":"Ito","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2025.117138_bib0027","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00093-17","article-title":"In vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant gram-negative bacilli from North America and Europe, including carbapenem-nonsusceptible isolates (SIDERO-WT-2014 Study)","volume":"61","author":"Hackel","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2025.117138_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2018.11.007","article-title":"In vitro activity of cefiderocol, a siderophore cephalosporin, against gram-negative bacilli isolated by clinical laboratories in North America and Europe in 2015\u20132016:SIDERO-WT-2015","volume":"53","author":"Karlowsky","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2025.117138_bib0029","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/jac\/dky425","volume":"74","author":"Hsueh","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2025.117138_bib0030","article-title":"Occurrence of high levels of cefiderocol resistance in carbapenem-resistant Escherichia coli before its approval in China: a report from China CRE-Network","volume":"10","author":"Wang","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.diagmicrobio.2025.117138_bib0031","doi-asserted-by":"crossref","unstructured":"Sato T., Ito A., Ishioka Y., Matsumoto S., Rokushima M., Kazmierczak K.M., et al., Escherichia coli strains possessing a four amino acid YRIN insertion in PBP3 identified as part of the SIDERO-WT-2014 surveillance study JAC Antimicrob Resist 2020; 2(3): dlaa081.","DOI":"10.1093\/jacamr\/dlaa081"},{"issue":"8","key":"10.1016\/j.diagmicrobio.2025.117138_bib0032","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1089\/mdr.2022.0279","article-title":"In vitro activity of cefiderocol against meropenem-nonsusceptible gram-negative Bacilli with defined \u03b2-lactamase carriage: SIDERO-WT surveillance studies, 2014\u20132019","volume":"29","author":"Wise","year":"2023","journal-title":"Microb Drug Resist"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889325004602?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889325004602?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T13:02:38Z","timestamp":1769518958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889325004602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0732889325004602"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2025.117138","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of essential antimicrobial agents, including ceftazidime\/avibactam, imipenem\/relebactam, and cefiderocol, against carbapenem-resistant Gram-negative bacteria primarily harboring the IMP-type carbapenemase gene in the Kinki region of Japan","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2025.117138","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117138"}}